landiolol has been researched along with Left Ventricular Dysfunction in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 13 (86.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Akitsu, K; Fujino, T; Ikeda, T; Kinoshita, T; Koike, H; Shinohara, M; Suzuki, T; Wada, R; Yano, K | 1 |
| Syed, YY | 1 |
| Fujimoto, Y; Hayashi, H; Hayashi, M; Ito-Hagiwara, K; Iwasaki, YK; Maru, E; Oka, E; Shimizu, W; Yamamoto, T; Yodogawa, K | 1 |
| Imamura, T; Nitta, D | 1 |
| Iwasaki, YK; Oka, E; Shimizu, W | 1 |
| Momomura, S | 1 |
| Aiba, T; Atarashi, H; Daimon, T; Fujino, K; Hori, M; Ikeda, T; Imai, Y; Inoue, H; Kinugawa, K; Kitakaze, M; Nagai, R; Nagano, T; Okamura, T; Sakamoto, A; Seino, Y; Shimizu, W; Yamashita, T | 2 |
| Arimoto, M; Hata, H; Ishii, Y; Osaka, S; Sezai, A; Shiono, M; Yaoita, H | 1 |
| Amiya, E; Endo, M; Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Nitta, D | 1 |
| Arashi, T; Haruyama, N; Mae, T; Takata, J | 1 |
| Doi, M; Fukuta, S; Kobayashi, S; Matsuzaki, M; Murakami, W; Nao, T; Okamura, T; Okuda, S; Susa, T; Tanaka, T; Wada, Y; Yamada, J; Yano, M | 1 |
| Yasumura, Y | 1 |
| Hayashida, Y; Ito, N; Kuwahara, G; Minematsu, N; Morishige, N; Nishimi, M; Sukehiro, Y; Tashiro, T; Teratani, H | 1 |
| Hirai, H; Minamiyama, Y; Sakaguchi, M; Sasaki, Y; Shibata, T; Suehiro, S; Takahashi, Y; Takemura, S | 1 |
1 review(s) available for landiolol and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Landiolol: A Review in Tachyarrhythmias.
Topics: Administration, Intravenous; Adrenergic beta-1 Receptor Antagonists; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Approval; Heart Failure; Heart Rate; Humans; Japan; Morpholines; Tachycardia; Tachycardia, Supraventricular; Treatment Outcome; Urea; Ventricular Dysfunction, Left | 2018 |
4 trial(s) available for landiolol and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study).
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Female; Heart Rate; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Tachycardia; Urea; Ventricular Dysfunction, Left | 2013 |
Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Digoxin; Drug Monitoring; Female; Heart Rate; Humans; Male; Middle Aged; Morpholines; Severity of Illness Index; Stroke Volume; Treatment Outcome; Urea; Ventricular Dysfunction, Left | 2014 |
Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventric
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans; Male; Morpholines; Postoperative Complications; Prospective Studies; Urea; Ventricular Dysfunction, Left | 2015 |
Safety and efficacy of an ultrashort-acting β1-blocker on left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Morpholines; Premedication; Urea; Ventricular Dysfunction, Left | 2012 |
10 other study(ies) available for landiolol and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Comparison of Landiolol and Digoxin as an Intravenous Drug for Controlling the Heart Rate in Patients with Atrial Fibrillation and Severely Depressed Left Ventricular Function.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Digoxin; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Severity of Illness Index; Stroke Volume; Tachycardia; Treatment Outcome; Urea; Ventricular Dysfunction, Left | 2020 |
Differential Effectiveness of Landiolol Between Atrial Fibrillation and Atrial Flutter/Atrial Tachycardia Patients With Left Ventricular Dysfunction.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Tachycardia; Urea; Ventricular Dysfunction, Left | 2019 |
What Determines the Response to Landiolol?
Topics: Atrial Fibrillation; Atrial Flutter; Humans; Morpholines; Tachycardia; Urea; Ventricular Dysfunction, Left | 2019 |
What Determines the Response to Landiolol? - Reply.
Topics: Atrial Fibrillation; Atrial Flutter; Humans; Morpholines; Tachycardia; Urea; Ventricular Dysfunction, Left | 2019 |
Acute rate control in atrial fibrillation with left ventricular dysfunction.
Topics: Adrenergic beta-1 Receptor Antagonists; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Female; Heart Rate; Humans; Male; Morpholines; Tachycardia; Urea; Ventricular Dysfunction, Left | 2013 |
An Experience of Landiolol Use for an Advanced Heart Failure Patient With Severe Hypotension.
Topics: Adrenergic beta-1 Receptor Antagonists; Atrial Fibrillation; Biological Availability; Cardiomyopathy, Dilated; Electrocardiography; Heart Failure; Humans; Hypotension; Intra-Aortic Balloon Pumping; Male; Mitral Valve Insufficiency; Morpholines; Severity of Illness Index; Treatment Outcome; Urea; Ventricular Dysfunction, Left; Young Adult | 2015 |
Alteration of fatal 1:1 conducted atrial flutter to less conducted ratio by landiolol infusion.
Topics: Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Humans; Male; Morpholines; Urea; Ventricular Dysfunction, Left | 2016 |
Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Cardiotonic Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Japan; Male; Middle Aged; Milrinone; Morpholines; Prospective Studies; Pulmonary Wedge Pressure; Recovery of Function; Stroke Volume; Time Factors; Treatment Outcome; Urea; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
Combination of β-blocker and milrinone for acute heart failure.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Male; Milrinone; Morpholines; Urea; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
Pre-ischemic administration of landiolol prevents ischemia-reperfusion injury in the rat heart.
Topics: Adrenergic beta-Antagonists; Animals; Dose-Response Relationship, Drug; Heart; Ischemic Preconditioning, Myocardial; Male; Morpholines; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Reperfusion Injury; Urea; Ventricular Dysfunction, Left | 2007 |